Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immuno...
Antengene Corporation Limited, a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing fir...
Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceutical...
Affibody AB announced that the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy (RLT) cand...
The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with stron...
Neurotechnology company Neupulse has announced a first-of-its-kind wearable device proven to dramatically reduce the frequency and urge of tics in people l...
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CL...
Australian biotechnology pioneer Vaxxas Pty Ltd, has been granted a licence by the Therapeutic Goods Administration (TGA) to manufacture the Company&rsqu...
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuropla...
Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in Gout Acquisition expected to be highly accretive to...
Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (n...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the EPO notified the...
Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced the s...
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology ta...
© 2025 Biopharma Boardroom. All Rights Reserved.
